Reply to The Emerging Role of Atypical Antipsychotics in the Treatment of Tardive Dyskinesia Induced by Other Atypical Antipsychotics
J Clin Psychiatry 2011;72(7):1016-1017 [letter]
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
We appreciate the comments made by Peritogiannis and Tsouli regarding our recently published article. We agree that researchers should focus on studying the use of other second-generation antipsychotics (SGAs) to treat patients with SGA-induced tardive dyskinesia. This kind of study has both clinical and etiologic implications for tardive dyskinesia.